Biotechnology News and Research

RSS

Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes

Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, today announced a study of obese primates treated with RM-493 showing a reversal of obesity and insulin resistance, and improvement in both heart rate and blood pressure. RM-493 is a novel peptide agonist targeting the melanocortin 4 receptor (MC4R) that is a clinical candidate for the treatment of obesity and diabetes.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

NTU, Technion announce new collaboration to jointly offer PhD programme

Singapore's leading science and technology university, Nanyang Technological University, and Israel's number one university, Technion-Israel Institute of Technology, today announced a new collaboration to jointly offer a Doctor of Philosophy programme.

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Cernostics, Geisinger announce personalized healthcare collaboration

Cernostics Inc., a biotechnology firm specializing in advanced cancer diagnostics, and Geisinger Health System, a $2.1 billion integrated health services organization, today announced a partnership in personalized healthcare. They will focus on developing diagnostic technologies to detect subtle differences in the cellular and molecular makeup of patient tissue samples. These technologies promise to more effectively predict disease progression and identify patients who are most likely to be receptive to specific cancer treatments.

22 Jun 2010

Sinapis initiates dosing in Phase I trial of intravenous infusion of methamphetamine

Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.

21 Jun 2010

Simulations Plus third-quarter consolidated preliminary revenues up 14.9% to $3.1M

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today released preliminary revenues for its third fiscal quarter ended May 31, 2010.

21 Jun 2010

AMRI board approves new $10 million share repurchase program

AMRI today announced that its board of directors has approved a new share repurchase program of up to $10 million. Under the program, the company is authorized to repurchase outstanding shares of its Common Stock in the open market or in private transactions. Shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to price ranges set by management and regulatory considerations.

21 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy.

21 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Thomson Reuters' The Outpartnering Registry available for all organizations developing drugs

Thomson Reuters announced today that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around the world.

21 Jun 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Talecris CEO receives Ernst & Young Entrepreneur Of The Year 2010 Award

Lawrence D. Stern, chairman and CEO of Talecris Biotherapeutics, received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the health sciences category in the Carolinas at a ceremony last night in Charlotte, N.C. The Ernst & Young awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses.

19 Jun 2010

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

Spectrum Pharmaceuticals, Inc. today announced that it has adjourned its Annual Meeting of Stockholders to 10:30a.m. Pacific Time, Thursday, July 1, 2010, which will be held at the Company's corporate office located at 157 Technology Drive, Irvine, California, 92618.

19 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.

19 Jun 2010

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

19 Jun 2010

BioTime announces warrant discount offer

BioTime, Inc. announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share.

19 Jun 2010

AdnaGen signs option agreement to license specific antibodies to KellBenx

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.

19 Jun 2010

Akela Pharma first-quarter net loss reduces to $0.4 million

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months ended March 31, 2010.

19 Jun 2010

Biotechnology News and Research

Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes

Biodesix awarded US patent for VeriStrat serum test

NTU, Technion announce new collaboration to jointly offer PhD programme

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Cernostics, Geisinger announce personalized healthcare collaboration

Sinapis initiates dosing in Phase I trial of intravenous infusion of methamphetamine

Simulations Plus third-quarter consolidated preliminary revenues up 14.9% to $3.1M

AMRI board approves new $10 million share repurchase program

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

Exelixis announces regaining of rights to develop and commercialize XL184

Thomson Reuters' The Outpartnering Registry available for all organizations developing drugs

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Talecris CEO receives Ernst & Young Entrepreneur Of The Year 2010 Award

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

BioTime announces warrant discount offer

AdnaGen signs option agreement to license specific antibodies to KellBenx

Akela Pharma first-quarter net loss reduces to $0.4 million

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News